What CSG.BIO does

CSG.BIO is a Scottsdale, Arizona-based global life sciences company that operates an integrated platform across three service lines: reproductive fertility, newborn stem cell banking, and regenerative medicine. The company serves over 500,000 families across North America, Asia, Europe, and the GCC region (with operations in the UAE via Abu Dhabi Stem Cells Center partnership), and has stored more than 1 trillion spermatozoa and 950,000+ stem cell units. Its service portfolio is delivered through seven wholly-owned or affiliated brands — CellSave (newborn stem cell banking in GCC), CryoChoice (at-home male fertility testing, U.S.), AlphaCord (private stem cell banking, U.S.), New England Fertility Institute (full-service fertility clinic, Stamford, CT), Hanabusa IVF (mini-IVF clinic, San Diego, CA), Asian Egg Bank (donor egg platform), and My Pregnancy Arabia (prenatal education events platform in GCC).

The underlying technology is a cryogenic preservation and storage platform that handles cord blood, cord tissue, placental tissue, amnion tissue, exosomes, and clinical-grade MSCs. Notable technical differentiators include multi-site geographic storage for redundancy, proprietary MSC banking technology that enables repeated use of preserved cells for virtually unlimited doses, GMP-certified processing laboratories (via the Bioscience Institute partnership), and a patented mail-in semen analysis and cryopreservation workflow pioneered by CryoChoice. The company processes 950,000+ stem cell units with a 100% claimed sample success rate and has released units for clinical use.

CSG.BIO's revenue mechanics span professional services (IVF/IUI/egg-freezing cycles, regenerative treatments), recurring subscription storage fees (long-term stem cell preservation), one-time payments (at-home sperm cryopreservation kits), and transaction/event fees (My Pregnancy Arabia exhibitions with 200+ brand partners). Go-to-market is primarily direct-to-consumer via clinical locations and DTC shipping channels, with a secondary B2B layer for regenerative medicine through healthcare provider partnerships and OEM/embedded distribution via the Bioscience Institute. Customer segments center on fertility patients/couples, expectant parents seeking newborn stem cell preservation, regenerative medicine patients, and GCC-region expectant mothers. The company is privately held, has no disclosed venture funding, and has grown through a roll-up strategy of branded acquisitions (AlphaCord/CryoChoice in 2021; Hanabusa IVF/Asian Egg Bank in March 2026).

Name

CSG.BIO

Legal name

CSG.BIO

Website

https://csg.bio

Company type

Private

Founded year

2000

Operating status

Operating

Headcount range

1–10 employees

Short description

CSG.BIO is a global life sciences platform providing fertility treatments, newborn stem cell banking, and regenerative medicine services across North America, Asia, Europe, and the GCC, serving over 500,000 families through seven specialized consumer brands.

Ownership category

akta.pro rank

Product category

Fertility and Reproductive Medicine Services

NAICS

Blood and Organ Banks (621991), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Cell & Tissue Banking (biobanking, cord blood/tissue) (HLAAAGAE)

akta.pro secondary industry

Fertility, Reproductive Endocrinology & IVF Centers (HLAFAJAD)

Keywords

• Fertility treatment services
• Newborn stem cell banking
• Cryopreservation services
• Reproductive medicine
• Prenatal education

Headquarters

HQ city

Scottsdale

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales

Revenue model

1. Fertility and reproductive services: Revenue generated from fertility treatments including IVF, IUI, egg freezing, donor egg services, surrogacy programs, and mini-IVF treatments through New England Fertility Institute, Hanabusa IVF, and Asian Egg Bank
2. Stem cell processing and storage: Fees from processing, testing, and long-term cryogenic storage of cord blood, cord tissue, placental tissue, amnion tissue, exosomes, and clinical-grade ready-to-use MSCs through CellSave, AlphaCord, and related brands
3. At-home male fertility services: Revenue from peer-reviewed, at-home semen analysis kits and long-term cryogenic storage via CryoChoice
4. Regenerative medicine treatments: Access to cutting-edge regenerative medicine treatments for orthopedics, ovarian rejuvenation, erectile dysfunction, body performance and enhancements, skin rejuvenation, face enhancements, hair loss and more through Bioscience Institute partnership
5. Prenatal education events: Revenue from mega events and satellite events for expecting families through My Pregnancy Arabia platform, including partnerships with over 200+ local and international brands and exhibitors

Go-to-market motion1 record

Distribution channels5 records

Marketing channels1 record

Core offering

CSG.BIO is a global life sciences company that delivers fertility treatments (IVF, IUI, egg freezing, surrogacy, at-home sperm cryopreservation), newborn stem cell cryopreservation and long-term storage (cord blood, cord tissue, placental tissue, amnion tissue, exosomes, MSCs), and regenerative medicine treatments (orthopedics, ovarian rejuvenation, skin and hair therapies) to families and patients. Services are sold directly to consumers through a portfolio of wholly-owned brands (CellSave, CryoChoice, AlphaCord, New England Fertility Institute, Hanabusa IVF, Asian Egg Bank, My Pregnancy Arabia) across North America, Asia, Europe, and the GCC region.

Product overview

CSG.BIO is a global life sciences company operating a platform-based model that unifies reproductive fertility, newborn stem cell, and regenerative medicine services. The platform encompasses four core service areas: Newborn Stem Cells (cryopreservation of cord blood, cord tissue, placental tissue, amnion tissue, exosomes, and MSCs), Reproductive Fertility (IVF, IUI, egg freezing, surrogacy, and sperm preservation), Regenerative Medicine (treatments for orthopedics, ovarian rejuvenation, and more), and Prenatal Education. The company manages a portfolio of acquired and affiliated brands including CellSave, Asian Egg Bank, CryoChoice, AlphaCord, New England Fertility Institute, Hanabusa IVF, and My Pregnancy Arabia, providing integrated services across North America, Asia, and Europe.

Differentiator

Problem solved

Functional benefit

Brands

• CellSave: Newborn stem cell processing and storage services in GCC region
• CryoChoice
• AlphaCord
• New England Fertility Institute (NFI)
• Hanabusa IVF
• Asian Egg Bank
• My Pregnancy Arabia

Products and services

• CellSave Newborn stem cell processing, testing, and cryogenic storage services for cord blood, cord tissue, placental tissue, amnion tissue, exosomes, and clinical-grade ready-to-use MSCs. Operated in partnership with ADSCC, it is the largest and most technologically advanced newborn stem cell laboratory in the GCC region and is widely recommended by OB/GYNs.
• CryoChoice At-home male fertility testing and sperm cryopreservation service; pioneered the first cost-effective, mail-in semen analysis and cryopreservation service. Serves as America's largest at-home fertility provider.
• AlphaCord Private stem cell banking provider offering cord blood and tissue banking services in the U.S., including processing and long-term cryogenic storage.
• New England Fertility Institute Premier full-service fertility clinic based in Stamford, Connecticut offering IVF, IUI, egg freezing, donation, and surrogacy programs using state-of-the-art clinical facilities.
• Hanabusa IVF San Diego-based fertility practice renowned for its personalized mini-IVF approach and lower-stimulation treatments designed to meet diverse patient needs.
• Asian Egg Bank Leading donor egg platform serving intended parents worldwide, specializing in Asian donor egg options, with associated surrogacy and family-building services.
• My Pregnancy Arabia Largest pregnancy educational community and event platform in the GCC region, hosting mega events, satellite events, and 100+ antenatal classes per year in partnership with 200+ local and international brands and exhibitors.

Quantifiable outcome

• 500,000+ families helped with fertility, stem cell and regenerative medicine services
• +3 more outcomes

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Seven partnerships are on record, tiered minor and core.

• Nixon PeabodyminorImplementation/ SI/ Consulting Partner · 23 March 2026Nixon Peabody LLP represented Hanabusa IVF and Asian Egg Bank in their partnership with CSG.BIO. The law firm's Healthcare counsel and Reproductive Medicine team led the transaction, providing legal counsel for the deal.
• Hanabusa IVFcoreStrategic or Co-development Partner · 5 March 2026Hanabusa IVF, a San Diego-based practice renowned for its personalized mini-IVF approach, has been acquired by CSG.BIO. The acquisition enhances CSG.BIO's reproductive medicine capabilities, combining Hanabusa's mini-IVF clinical model with CSG.BIO's existing fertility platform.
• Asian Egg BankcoreStrategic or Co-development Partner · 5 March 2026Asian Egg Bank, a leading donor egg platform serving intended parents worldwide with specialization in Asian donor options, has been acquired by CSG.BIO. The acquisition integrates specialized fertility, donor egg, surrogacy, and family-building services into CSG.BIO's platform.
• Venable LLPminorImplementation/ SI/ Consulting PartnerVenable LLP served as legal counsel alongside Nixon Peabody for Hanabusa IVF and Asian Egg Bank's partnership with CSG.BIO.
• Provident Healthcare PartnerscoreImplementation/ SI/ Consulting PartnerProvident Healthcare Partners served as the lead investment banker for Hanabusa IVF and Asian Egg Bank, advising them on their partnership with CSG.BIO. The transaction highlights continued demand for specialized fertility platforms.
• Bioscience InstitutecoreStrategic or Co-development PartnerStrategic partnership with Bioscience Institute enables CSG.BIO companies to provide customers with cutting-edge regenerative medicine treatments. The partnership offers access to GMP laboratories for stem cell processing and therapeutic applications.
• Abu Dhabi Stem Cells Center (ADSCC)coreStrategic or Co-development PartnerStrategic partnership with Abu Dhabi Stem Cells Center (ADSCC) launched in 2023. ADSCC is partnered with CellSave to operate the largest, most technologically advanced newborn stem cell laboratory in the GCC region.

Scale indicators7 records

Recent moves5 records

Expansion highlights6 records

Emerging players

• Legacy: Legacy provides mail-in male fertility testing and sperm cryopreservation with DTC positioning. Direct competitor to CryoChoice in the at-home male fertility space, though smaller in scale and without CSG.BIO's clinical integration.

Direct peers

• StemCyte: StemCyte is a global cord blood bank with operations in the US and Asia, also participating in regenerative medicine and clinical research. Comparable as an internationally distributed family and public cord blood bank, particularly in Asia.
• ViaCord (Revvity): ViaCord, owned by Revvity (formerly PerkinElmer), provides cord blood and cord tissue banking services to families. Directly comparable family stem cell banking service competing for the same expectant-parent segment as AlphaCord.
• Prelude Fertility (Inception Fertility): Inception Fertility is a large US fertility services platform operating Prelude Fertility clinics and MyEggBank. Closely comparable as a multi-brand IVF and egg banking platform pursuing a platform-consolidation strategy similar to CSG.BIO.
• Kindbody: Kindbody is a tech-enabled fertility clinic network offering IVF, egg freezing, and employer-sponsored fertility benefits across the US. Operates a multi-site fertility clinic platform analogous to CSG.BIO's New England Fertility Institute and Hanabusa IVF combined footprint.
• Cryo-Cell International: Public US cord blood banking company offering family cord blood and menstrual stem cell banking services. Most direct public-market peer in family newborn stem cell banking and cryogenic storage, with subscription revenue model analogous to CSG.BIO's CellSave and AlphaCord brands.
• California Cryobank (CCB Life Sciences): California Cryobank is one of the largest US sperm banks and reproductive tissue banks, offering donor sperm, egg donation, and long-term storage. Directly comparable to CSG.BIO's CryoChoice (sperm cryopreservation) and Asian Egg Bank businesses.

Regional players

• Smart Cells International: Smart Cells is a UK-headquartered cord blood bank operating across the Middle East, including the GCC. Comparable to CellSave for family stem cell banking in overlapping GCC territories; illustrates regional competitive dynamics for CSG.BIO's GCC business.

Broad incumbents

• US Fertility (CCRM): US Fertility operates CCRM, one of the largest US fertility clinic networks, offering IVF, egg freezing, and genetic services. Directly comparable as a multi-clinic IVF platform; larger and more geographically distributed than CSG.BIO's clinic portfolio.
• CooperSurgical (parent: CooperCompanies): CooperSurgical is the largest US fertility and reproductive medicine conglomerate, owning Cord Blood Registry (CBR), Wallace, and many IVF/genetic-testing brands. Directly comparable as a diversified fertility and cell-banking platform, but operating at a much larger scale and with broader product breadth than CSG.BIO.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/csgbio

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CSG.BIO